Evidence mapPaperPMID 36807492Full record

Observational studyDiabetes care2023

Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration.

Peter D Reaven, Michelle Newell, Salvador Rivas, Xinkai Zhou, Gregory J Norman, Jin J Zhou

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Clin-STAR Corner: Practice Changing Advances in Diabetes Care.Journal of the American Geriatrics Society · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Peter D ReavenPhoenix Veterans Affairs Health Care System, Phoenix, AZ.
Michelle NewellPhoenix Veterans Affairs Health Care System, Phoenix, AZ.ORCID 0000-0003-1198-1062
Salvador RivasPhoenix Veterans Affairs Health Care System, Phoenix, AZ.
Xinkai ZhouMedicine and Biostatistics, University of California Los Angeles, Los Angeles, CA.
Gregory J NormanDexcom, Inc., San Diego, CA.ORCID 0000-0001-7989-9597
Jin J ZhouPhoenix Veterans Affairs Health Care System, Phoenix, AZ.
Phoenix VA Health Care System · USUniversity of California, Los Angeles · USDexcom (United States) · US

Funding

NHGRI NIH HHS R01 HG006139NHLBI NIH HHS R21 HL150374
6 · The paper itself

Abstract

objectiveTo determine the benefit of starting continuous glucose monitoring (CGM) in adult-onset type 1 diabetes (T1D) and type 2 diabetes (T2D) with regard to longer-term glucose control and serious clinical events. RESEARCH DESIGN AND

methodsA retrospective observational cohort study within the Veterans Affairs Health Care System was used to compare glucose control and hypoglycemia- or hyperglycemia-related admission to an emergency room or hospital and all-cause hospitalization between propensity score overlap weighted initiators of CGM and nonusers over 12 months.

resultsCGM users receiving insulin (n = 5,015 with T1D and n = 15,706 with T2D) and similar numbers of nonusers were identified from 1 January 2015 to 31 December 2020. Declines in HbA1c were significantly greater in CGM users with T1D (-0.26%; 95% CI -0.33, -0.19%) and T2D (-0.35%; 95% CI -0.40, -0.31%) than in nonusers at 12 months. Percentages of patients achieving HbA1c <8 and <9% after 12 months were greater in CGM users. In T1D, CGM initiation was associated with significantly reduced risk of hypoglycemia (hazard ratio [HR] 0.69; 95% CI 0.48, 0.98) and all-cause hospitalization (HR 0.75; 95% CI 0.63, 0.90). In patients with T2D, there was a reduction in risk of hyperglycemia in CGM users (HR 0.87; 95% CI 0.77, 0.99) and all-cause hospitalization (HR 0.89; 95% CI 0.83, 0.97). Several subgroups (based on baseline age, HbA1c, hypoglycemic risk, or follow-up CGM use) had even greater responses.

conclusionsIn a large national cohort, initiation of CGM was associated with sustained improvement in HbA1c in patients with later-onset T1D and patients with T2D using insulin. This was accompanied by a clear pattern of reduced risk of admission to an emergency room or hospital for hypoglycemia or hyperglycemia and of all-cause hospitalization.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HyperglycemiaHypoglycemiaAdultBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsInsulinInsulin, Regular, HumanRetrospective StudiesVeterans HealthBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin, Regular, Human

Identifiers

PMID36807492
PMCPMC10260873
OpenAlexW4321182761

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.